Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis

Jason Liebowitz, MD, FACR  |  Issue: August 2021  |  June 28, 2021

In this observational study, residual, unmeasured confounders may explain the apparent association between glucosamine use and reduced mortality. Example: Patients taking regular glucosamine supplements may be more likely to engage in other beneficial health-related behaviors than those patients not regularly taking glucosamine supplements. Thus, glucosamine use may simply be a surrogate marker for healthy behaviors that affect mortality.

Dr. Chevalier noted patients often ask about other supplements and dietary interventions and the role these entities may play in management of OA. One of the most frequently discussed alternative therapies is turmeric, a spice that comes from the Curcuma longa plant.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a randomized, double-blind, placebo-controlled trial of 70 patients with symptomatic knee OA and effusion synovitis as identified by ultrasound, two capsules of Curcuma longa extract were given daily to the intervention group for 12 weeks. The two primary outcomes of the study were changes in knee pain on a visual analog scale (VAS) and effusion synovitis volume assessed by magnetic resonance imaging (MRI).4

At 12 weeks, the intervention group improved the VAS pain score by –9.1 mm (95% CI, –17.8 to –0.4 mm; P=0.039) by comparison to the placebo group. However, the between-group change in effusion synovitis volume as assessed by MRI was 3.2 mL (95% CI, –0.3 to 6.8; P=0.075), which was not statistically significant. These results may indicate some symptomatic benefit may be accrued with the turmeric use, but longer follow-up may be necessary to detect any improvement in objective measures of knee effusion or synovitis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Hand OA can be a particularly debilitating and difficult-to-treat condition. Thus, it’s helpful to understand if existing treatments for other forms of arthritis are worthwhile to try in patients with this condition.

On this note, Dr. Chevalier referenced a study by Davis et al., which investigated the effect of 1 mg of daily colchicine vs. placebo on hand pain and function for 12 weeks in older patients (aged 48–79 years) with hand OA. A total of 64 patients were enrolled and randomized to receive colchicine or placebo. The primary outcome was the VAS hand pain score, and secondary outcomes were tender and swollen joint count, grip strength, C-reactive protein level, Michigan Hand Outcomes Questionnaire total, function and pain scores. Unfortunately, no statistically significant differences were seen between the intervention and control groups for any of the primary or secondary outcomes.5 These disappointing results indicate the quest continues to find effective therapies for the management of hand OA.

The Future

What is on the horizon for OA treatment? Nerve growth factor (NGF) inhibitors are certainly an interesting area of future research. NGF plays a critical role in pain modulation and, thus, represents a potential therapeutic target in the treatment of OA. Additionally, sprifermin, a recombinant human fibroblast growth factor 18, is currently under investigation as a potential disease-modifying medication for OA.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:dietary supplementEULARhandhand osteoarthritisKnee Osteoarthritis (OA)osteoarthritis (OA)

Related Articles

    How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

    June 9, 2023

    My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

    Exercise Therapy Recommended to Manage Knee Osteoarthritis

    July 12, 2016

    The benefits of exercise therapy for individuals with knee osteoarthritis (OA) are well known. The ACR strongly recommends both aquatic exercise and land-based aerobic and resistance exercise for managing knee OA.1 A recent Cochrane systematic review and meta-analysis concluded that high-quality evidence supports the use of exercise to reduce pain and improve physical function and…

    Osteoarthritis Quo Vadis

    March 1, 2008

    Our knowledge of OA has progressed far—does a cure lie ahead?

    Glucosamine Supplements Don’t Help Knee or Hip Arthritis Pain

    August 10, 2017

    (Reuters Health)—Oral glucosamine has no more effect than placebo on joint pain, according to a new meta-analysis. The analysis of randomized controlled trials from which data have been made public found that at both three-month and 24-month follow-up points, the supplement had no effect on either hip or knee pain from arthritis. ad goes here:advert-1ADVERTISEMENTSCROLL…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences